Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.

about

Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs in United States and Rest of World: A Subset Analysis.

Item

http://www.wikidata.org/entity/Q55251974

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@en

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@nl

type

Item

label

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@en

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@nl

prefLabel

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@en

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@nl

P1476

Baricitinib in Patients with R ...... t of World: A Subset Analysis.

@en

P2093

Alvin F Wells

http://www.w3.org/2001/XMLSchema#string

Cynthia E Kartman

http://www.w3.org/2001/XMLSchema#string

Jahangir Alam

http://www.w3.org/2001/XMLSchema#string

John D Bradley

http://www.w3.org/2001/XMLSchema#string

Maria Greenwald

http://www.w3.org/2001/XMLSchema#string

Vipin Arora

http://www.w3.org/2001/XMLSchema#string

P2860

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

Janus kinase inhibitors in autoimmune diseases

The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis.

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.

Therapeutic strategies for rheumatoid arthritis.

Use of disease-modifying medications for rheumatoid arthritis by race and ethnicity in the National Ambulatory Medical Care Survey.

Impact of baseline anti-cyclic citrullinated peptide-2 antibody concentration on efficacy outcomes following treatment with subcutaneous abatacept or adalimumab: 2-year results from the AMPLE trial

Racial disparities in treatment preferences for rheumatoid arthritis

Geographic variation in rheumatoid arthritis incidence among women in the United States.

P2888

s40744-018-0110-x

P304

43-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40744-018-0110-X

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1103506703

http://www.w3.org/2001/XMLSchema#string

P698

29680881

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq

P932

5935623

http://www.w3.org/2001/XMLSchema#string